interferon beta-1b betaseron  (Bayer US LLC)

Journal: BMC Neurology

Article Title: Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

doi: 10.1186/1471-2377-14-49

Figure Lengend Snippet: Characteristics of persons contacted, excluded, lost, and enrolled

Article Snippet: Inclusion criteria for TOP MS included males and females, 18 years of age or older, with a diagnosis of MS, who were continuing or initiating treatment with approved doses of glatiramer acetate (GA, Copaxone, Teva Pharmaceuticals, Inc.), intramuscular or subcutaneous interferon beta-1a (IFNβ-1a IM; Avonex, Biogen Idec; IFNβ-1a SC, Rebif, EMD-Serono), or interferon beta-1b (IFNβ-1b, Betaseron, Bayer Pharmaceuticals, Inc.).

Techniques:

Journal: BMC Neurology

Article Title: Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

doi: 10.1186/1471-2377-14-49

Figure Lengend Snippet: Baseline disease characteristics of prevalent MS patients

Article Snippet: Inclusion criteria for TOP MS included males and females, 18 years of age or older, with a diagnosis of MS, who were continuing or initiating treatment with approved doses of glatiramer acetate (GA, Copaxone, Teva Pharmaceuticals, Inc.), intramuscular or subcutaneous interferon beta-1a (IFNβ-1a IM; Avonex, Biogen Idec; IFNβ-1a SC, Rebif, EMD-Serono), or interferon beta-1b (IFNβ-1b, Betaseron, Bayer Pharmaceuticals, Inc.).

Techniques: Isolation

Journal: Neurology and Therapy

Article Title: A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector

doi: 10.1007/s40120-022-00323-1

Figure Lengend Snippet: Study inclusion and exclusion criteria

Article Snippet: Interferon beta-1b (Betaseron, Bayer US LLC, Whippany, NJ, USA) is a type of DMT for patients with CIS or RRMS.

Techniques: Biomarker Discovery

Journal: Neurology and Therapy

Article Title: A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector

doi: 10.1007/s40120-022-00323-1

Figure Lengend Snippet: Patient demographics

Article Snippet: Interferon beta-1b (Betaseron, Bayer US LLC, Whippany, NJ, USA) is a type of DMT for patients with CIS or RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector

doi: 10.1007/s40120-022-00323-1

Figure Lengend Snippet: Adherence rates among patients

Article Snippet: Interferon beta-1b (Betaseron, Bayer US LLC, Whippany, NJ, USA) is a type of DMT for patients with CIS or RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector

doi: 10.1007/s40120-022-00323-1

Figure Lengend Snippet:

Article Snippet: Interferon beta-1b (Betaseron, Bayer US LLC, Whippany, NJ, USA) is a type of DMT for patients with CIS or RRMS.

Techniques:

Journal: American Health & Drug Benefits

Article Title: Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008–2018

doi:

Figure Lengend Snippet: FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis

Article Snippet: Interferon beta-1b (subcutaneous) , Betaseron , July 1993 , Bayer Healthcare.

Techniques:

Journal: American Health & Drug Benefits

Article Title: Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008–2018

doi:

Figure Lengend Snippet: Classification of Each Disease-Modifying Therapy for Multiple Sclerosis

Article Snippet: Interferon beta-1b (subcutaneous) , Betaseron , July 1993 , Bayer Healthcare.

Techniques: